Southern Company (The) 2025 Series A Corporate Units (SOMN)

Total Costs & Expenses

$5.20B

Quarterly · Period ending: · USD

SOMN logo

SOMN Total Costs & Expenses

Latest reported$5.20B
SOMN Quarterly Total Costs & Expenses ($1.92B → $5.20B)
High-resolution chart · PNG

SOMN total costs & expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Southern Company (The) 2025 Series A Corporate Units Total Costs & Expenses — Quarterly (USD)
Period endingTotal Costs & Expenses (USD)
5,201,000,000
6,379,000,000
6,070,000,000
5,229,000,000
5,209,000,000
5,765,000,000
5,283,000,000
4,906,000,000
4,524,000,000
4,943,000,000
4,838,000,000
4,870,000,000
4,458,000,000
5,262,000,000
6,909,000,000
6,185,000,000
5,551,000,000
5,264,000,000
6,098,000,000
4,515,000,000
4,490,000,000
4,312,000,000
4,388,000,000
3,785,000,000
3,562,000,000
3,755,000,000
4,224,000,000
3,982,000,000
3,756,000,000
1,721,000,000
4,759,000,000
3,985,000,000
5,564,000,000
4,996,000,000
4,834,000,000
4,210,000,000
7,079,000,000
4,519,000,000
4,594,000,000
4,347,000,000
3,274,000,000
3,052,000,000
2,990,000,000
3,752,000,000
3,239,000,000
3,226,000,000
3,456,000,000
4,061,000,000
3,364,000,000
3,944,000,000
3,128,000,000
3,526,000,000
3,606,000,000
3,572,000,000
3,703,000,000
3,309,000,000
3,038,000,000
2,838,000,000
3,696,000,000
5,428,000,000
4,521,000,000
4,012,000,000
3,771,352,000
5,320,000,000
4,208,000,000
4,157,000,000
3,510,047,000
3,266,206,000
3,885,164,000
3,666,307,000
3,802,404,000
5,426,499,000
4,215,187,000
3,682,910,000
3,340,360,000
4,832,043,000
3,771,928,000
3,408,669,000
3,151,859,000
4,549,378,000
3,591,503,000
3,063,260,000
3,167,461,000
4,357,883,000
3,119,646,000
2,787,030,000
2,719,985,000
3,440,805,000
3,008,895,000
2,732,315,000
2,538,629,000
3,300,847,000
2,823,964,000
2,548,354,000
2,456,632,000
3,248,008,000
2,630,772,000
2,213,588,000
2,159,217,000
3,164,461,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.